Vandetanib With Everolimus
The goal of this clinical research study is to find the highest tolerable dose of the combination of vandetanib and everolimus that can be given to patients with advanced cancer. The effects of the study drugs at different dose levels and the safety of the study drugs will also be studied.
Vandetanib and everolimus are both designed to harm cancer cells, stopping their growth. This may stop or slow the growth or spread of cancer cells.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer|
- Maximum Tolerated Dose (MTD) of Vandetanib with Everolimus [ Time Frame: 28 days ] [ Designated as safety issue: No ]Maximum tolerated dose (MTD) defined as highest dose studied in which incidence of dose limiting toxicity (DLT) less than 33%. MTD defined by DLTs that occur in first 28-day cycle (induction phase).
|Study Start Date:||May 2012|
|Estimated Primary Completion Date:||May 2026 (Final data collection date for primary outcome measure)|
Experimental: Vandetanib + Everolimus
Starting dose of Vandetanib: 100 mg by mouth daily in a 28 day cycle.
Starting dose of Everolimus: 2.5 mg by mouth daily in a 28 day cycle.
Starting Dose: 100 mg by mouth daily in a 28 day cycle.
Other Names:Drug: Everolimus
Starting dose: 2.5 mg by mouth daily of a 28 day cycle.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01582191
|Contact: Vivek Subbiah, MD||713-563-0393|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Vivek Subbiah, MD||M.D. Anderson Cancer Center|